Custom Antibody Market

Custom Antibody Market by Service (Antibody Development, Production, Labelling), Type (Monoclonal, Polyclonal, Recombinant), Source (Rabbit, Mice), Research Area (Oncology, Immunology), End User (Pharmaceutical Companies, CRO's) - Global Forecast to 2026

Report Code: BT 6817 May, 2021, by marketsandmarkets.com

[189 Pages Report] The global custom antibody market is projected to reach USD 652 million by 2026 from USD 393 million in 2021, at a CAGR of 10.6% during the forecast period. As such, an increase in research activity-especially in the life sciences industry-along with growing industry-academia collaborations are the primary growth drivers for this market. In addition, the objective behind custom antibody production is to acquire an antibody that performs well in a particular qualitative or quantitative immunodetection method. The quality of catalog antibodies (to ensure the reproducibility of results) is also an area of concern in this market, which is primarily why end users prefer custom-made antibodies.

Custom Antibody Market

To know about the assumptions considered for the study, download the pdf brochure

Covid-19 Impact On The Global Custom Antibody Market

A mix of established pharmaceutical companies, as well as small startups, have stepped forward to develop treatments and vaccines that target the infection caused by the novel coronavirus. Vaccine-related research activities in pharmaceutical and biotechnology companies, research centers, and academic research institutes are considered essential and have been largely unaffected in operations and output. Due to the increase in research activities, both the availability of funding for research and the demand for antibodies, including custom antibodies, are expected to grow.

Currently, several vaccines or antiviral drugs for COVID-19 have been approved or are under development, and patients are currently treated symptomatically. According to the WHO, there are 65 vaccine candidates, of which 9 candidates are already approved, and 56 are under development. At the forefront of the COVID-19 outbreak, many researchers worldwide are engaged in the viral research of SARS-CoV-2, the virus that causes COVID-19. For both vaccines and therapeutics, the antibodies produced are tested for their functional efficacy to neutralize the target virus.

The adoption of custom antibody services has increased for the development of COVID-19 vaccines. The companies operating in the custom antibody services market, including Thermo Fisher Scientific (US) and Abcam plc (US), witnessed a negative impact on their operations in Q1 and Q2 2020 due to the temporary shutdown of their laboratories. However, as lockdown restrictions were gradually lifted, research laboratories around the world started reopening. Most service providers prioritized actions to support the critical work of customers involved in COVID-19, such as offering a range of high-quality COVID-19 related research tools, reassigning R&D resources for developing critical products for SARS-Cov-2, boosting supply chain and manufacturing flexibility to support increased demand for existing products used for SARS-CoV-2/COVID-19 research, and entering into discussions and collaborations across the UK, US, and China focused on SARS-CoV-2 diagnostics, drugs, and vaccines development.

As per the H1 report published by Abcam plc., the company witnessed 6.7% growth in H1 2021 compared to H1 2020. Custom Products & Licensing (CP&L) revenue observed growth of 15.9%. Additionally, Thermo Fisher Scientific witnessed 15.2% growth in Q3 2020 as compared to Q3 2020. The services segment grew by 14.0% in Q3 2020 as compared to Q3 2020. Considering these trends, it can be stated that the impact of COVID-19 on the custom antibody market has been positive.

Custom Antibody:Market dynamics

Driver: Increasing research activities and funding

The R&D sector has conventionally remained capital-intensive due to long development periods and approval cycles. R&D investment occupies a prime position in global expenditure. Governments recognize R&D as a crucial investment for a nation’s progress, international competitiveness, and public benefit. Due to this, R&D expenditure and funding witnessed a steady increase over the years. According to the R&D Magazine (2020), in 2021, USD 2.5 trillion will be invested in R&D industries, government labs, and academic research centers across more than 115 countries. The R&D spending across the globe witnessed a drastic change due to the sudden outbreak of the COVID-19 pandemic. Various countries witnessed a massive decline in their respective R&D expenditures in 2020. On the other hand, China witnessed a historic R&D investment of 10.0% of its annual growth. The R&D shares of the top 10 countries in 2020 totaled 79.2%, and this figure is expected to remain the same in 2021. Currently, the rising demand for efficient therapeutic drugs with fewer side effects has led to an increasing focus on the R&D of biopharmaceuticals. The global pharmaceutical R&D sector accounts for about 80% of the overall R&D expenditure in the life sciences industry. Large pharmaceutical companies, such as F. Hoffmann-La Roche Ltd. (Switzerland), Merck KGaA (Germany), and Pfizer (US), account for a major portion of the biopharmaceutical sector’s R&D expenditure, investing nearly USD 50 billion annually. Similarly, the availability of funds from organizations for various genomic projects is boosting research in the field of genomics. An increase in research activity and the availability of funding is expected to drive the overall purchase and consumption of antibodies, in turn aiding the growth of the custom antibody market.

Opportunity: Increasing demand for personalized medicine in protein therapeutics

Personalized medicine, which has become a core area of research in the healthcare industry, has entered mainstream clinical practice and is changing the way many diseases are identified, classified, and treated. These advancements are particularly evident in the area of oncology. According to the Personalized Medicine Coalition report (2020), the number of personalized medicine drugs, treatments, and diagnostic products has increased since 2006, and this trend is expected to continue in the coming years. Moreover, biopharmaceutical companies have nearly doubled their R&D investments in personalized medicine over the last five years; this is further expected to increase by 33% over the next five years. The demand for protein therapeutics, including hormones, vaccines, monoclonal antibodies, blood factors, and therapeutic enzymes, has increased over the last few years. In addition, newly engineered protein therapeutics, such as bispecific mAbs and mAbs conjugated with small-molecule drugs, are in the developmental stage. Protein therapeutics has high recognition for its potential use in treating various kinds of diseases, and its demand has increased significantly in recent years, owing to the increasing prevalence of chronic diseases. For instance, Blinatumomab is a bispecific T-cell engager antibody (BiTE) approved by the FDA for relapsed or refractory B-cell precursors in cancer patients. Moreover, there are about 50 bispecific antibodies currently on clinical trials for various malignancies.

The growing demand for protein therapeutics and personalized medicine, coupled with the development of newly engineered proteins, is expected to open growth avenues for research markets in terms of the uptake of highly specific custom-made antibodies.

Challenges: Presence of Alternative Antibodies

The life science industry is witnessing an increasing number of reproducibility problems for various published papers, which has increased tenfold over the past decade. One of the major factors contributing to this reproducibility crisis is the use of poorly validated antibodies. The lot-to-lot variability and non-specific target binding affect research on a large scale. protein scaffolds are increasingly being used to detect proteins of interest. RNA or DNA aptamers and protein scaffolds can be engineered against a specific target and function, where the molecules are consistent from batch-to-batch and can be produced at a fraction of the cost of antibodies. Additionally, both affinity reagents are produced entirely in vitro and are not subject to the limitations of antibody production by animal immune systems. Their smaller size increases tissue penetration, enhancing access to epitopes within tissue sections to study proteins for which it is impossible to generate antibodies along with decreasing false negative immunohistochemistry results. The aforementioned advantages, along with their development to be functional in a wider range of conditions, including intracellular environments that degrade the antibody structure, open up applications such as super-resolution microscopy and intracellular live-cell imaging to investigate the molecular dynamics of diverse cellular processes. Thus, these antibody alternatives can be used to overcome the ongoing reproducibility crisis.

While these molecules improve research applications, their low molecular weight restricts their development into therapeutics. Various strategies are being employed by the industry to overcome this, such as adding an antibody domain or an albumin-binding domain to the scaffold or increasing the molecular weight of the protein scaffolds. The fusion of an antibody domain to a protein scaffold can also help engage the immune system for improved therapeutic benefit. Thus, the increase and improvement in the development of antibody alternatives may hamper the growth of the overall antibodies market in the coming years.

By services, the antibody development segment accounted for the largest share of the custom antibody market in 2020.

Based on service, the custom antibody market is segmented into antibody development, antibody production & purification, and antibody fragmentation & labeling. In 2020, the antibody development segment accounted for the largest share in the custom antibody market. The large share of this segment can be attributed to the increasing focus of researchers on high-quality custom antibodies for reproducibility, which can be hampered when using commercially available antibodies.

By type, the monoclonal antibody accounted for the largest share of the custom antibody market in 2020.

Based on type, the custom antibody market is segmented into monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and other custom antibodies. The monoclonal antibodies segment accounted for the largest market share in 2020. This is because monoclonal antibodies provide high specificity and selectivity compared to other antibodies and are thus the preferred choice in all types of research studies.

By source, the mice accounted for the largest share of the custom antibody market in 2020.

Based on source, the custom antibody market has been segmented into mice, rabbits, and other sources. The mice segment accounted for the largest share of the custom antibody market in 2020. Mice are the most preferred hosts for research-use antibody production. Compared to other experimental animals, mice offer advantages of lower feeding costs and ease of maintenance & handling due to their small size.

By research area, the oncology accounted for the largest share of the custom antibody market in 2020.

Based on the area of research, the custom antibody market is segmented into oncology, infectious diseases, neurobiology, stem cells, immunology, cardiovascular disease, and other research areas. The oncology segment accounted for the largest share of the custom antibody market in 2020. Cancer is one of the leading causes of death worldwide, which has led to an increase in cancer research and the proportion of therapeutic mAbs in research and clinical trials. This is a key factor responsible for the large share of the oncology segment.

By end user, the pharmaceutical and biopharmaceutical companies segment accounted for the largest share of the custom antibody market in 2020.

Based on end user, the custom antibody market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and contract research organizations. The pharmaceutical & biotechnology companies segment accounted for the largest share of in the custom antibody market in 2020. The increasing demand for high-specificity antibodies for drug discovery and development, increasing research in the areas of genomics and proteomics, the need for antibodies in the identification of new targets and assays, and increasing R&D activities in various therapeutic areas (such as cancer, HIV/AIDS, immunodeficiency diseases, and blood disorders) are the key factors driving the demand for custom antibodies by pharmaceutical & biotechnology companies

North America accounted for the largest share of the custom antibody market in 2020.

The custom antibody market is broadly segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share in the custom antibody market. The large share of this region can be attributed to the increasing investments in the development of structure-based drug designs, growing research in the fields of genomics and proteomics, rising demand for high-quality research tools for data reproducibility, and the increasing focus on developing antibody-based therapeutics. The presence of a large number of global players in this region is another key factor contributing to the large share of this market segment.

Custom Antibody Market  by Region

Key Market Players

Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), Merck Group (Germany), Cell Signaling Technology, Inc. (US), GenScript (China), BioLegend (US), Rockland Immunochemicals (US) are the prominent players operating in the custom antibody market.

Scope of the report

Report Metric

Details

Market Size Available for Years

2019–2026

Base Year Considered

2020

Forecast Period

2021–2026

Forecast Units

Value (USD)

Segments Covered

Service, Source, Type, Research Area and End User

Geographies Covered

North America, Europe, APAC, Latin America and Middle East & Africa

Companies Covered

The major market players include  as Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), Merck Group (Germany), Cell Signaling Technology, Inc. (US), GenScript (China), BioLegend (US), Rockland Immunochemicals (US) (Total 25 companies)

The study categorizes the custom antibody market into the following segments and subsegments:

Service

  • Antibody Development
  • Antibody Production & Purification
  • Antibody Fragmentation & Labeling

Type

  • Monoclonal Antibodies
  • Polyclonal Antibodies
  • Recombinant Antibodies
  • Other Custom Antibodies

Source

  • Mice
  • Rabbits
  • Other Sources

Research Area

  • Oncology
  • Infectious Diseases
  • Neurobiology
  • Stem Cells
  • Immunology
  • Cardiovascular Disease
  • Other Research Areas

End User

  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Contract Research Organizations

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Rest of Asia Pacific
  • Latin America
  • The Middle East and Africa

Recent Developments

  • In 2021, GenScript and SunRock Biopharma entered into a collaboration to develop therapeutic antibody candidates. GenScript will provide solutions to SunRock Biopharma for antibody discovery, cell line development, process development for GMP drug substances, and drug product manufacturing services.
  • In 2021, Abcam plc and Abingdon Health (UK) entered into a collaboration and co-marketing agreement to increase Abcam’s customer base.
  • In 2020, Thermo Fisher Scientific and BATL at Northeastern University entered into a collaborative agreement to advance analytical capabilities and drive innovation across the biopharmaceutical industry in various areas, including personalized medicine, monoclonal antibodies, and gene and cell therapies.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 17)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 23)
    2.1 RESEARCH DATA
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
           2.1.3 DATA TRIANGULATION
    2.2 MARKET ESTIMATION METHODOLOGY
           2.2.1 INSIGHTS FROM PRIMARY EXPERTS
    2.3 MARKET GROWTH RATE PROJECTIONS
    2.4 RESEARCH ASSUMPTIONS
    2.5 RISK ANALYSIS

3 EXECUTIVE SUMMARY (Page No. - 29)

4 PREMIUM INSIGHTS (Page No. - 35)
    4.1 CUSTOM ANTIBODY MARKET OVERVIEW
    4.2 NORTH AMERICA: CUSTOM ANTIBODY MARKET SHARE, BY TYPE & COUNTRY (2020)
    4.3 CUSTOM ANTIBODY MARKET SHARE, BY SOURCE (2020)
    4.4 CUSTOM ANTIBODY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW (Page No. - 38)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           5.2.1 MARKET DRIVERS
                    5.2.1.1 Increasing research activities and funding
                    5.2.1.2 Quality concerns over catalog antibodies
                    5.2.1.3 Growing industry-academia collaborations
                    5.2.1.4 Increasing focus on therapeutic antibodies and extensive pipeline drugs
           5.2.2 MARKET RESTRAINTS
                    5.2.2.1 Cost- and time-intensive antibody development process
           5.2.3 MARKET OPPORTUNITIES
                    5.2.3.1 High growth opportunities in developing countries
                    5.2.3.2 Increasing demand for personalized medicine in protein therapeutics
                    5.2.3.3 Increasing focus on biomarker discovery
           5.2.4 MARKET CHALLENGES
                    5.2.4.1 Presence of alternative antibodies
    5.3 PORTER’S FIVE FORCES ANALYSIS
           5.3.1 THREAT OF NEW ENTRANTS
           5.3.2 THREAT OF SUBSTITUTES
           5.3.3 BARGAINING POWER OF SUPPLIERS
           5.3.4 BARGAINING POWER OF BUYERS
           5.3.5 DEGREE OF COMPETITION
    5.4 TECHNOLOGICAL ANALYSIS
           5.4.1 CUSTOM ANTIBODY SERVICES
    5.5 PATENT ANALYSIS
    5.6 PRICING ANALYSIS
    5.7 REGULATORY LANDSCAPE
    5.8 IMPACT OF COVID-19 ON THE CUSTOM ANTIBODY MARKET
    5.9 VALUE CHAIN ANALYSIS OF THE CUSTOM ANTIBODY MARKET
    5.10 KEY INDUSTRY TRENDS
           5.10.1 INCREASING FOCUS ON ANTIBODY DRUG CONJUGATE
           5.10.2 INCREASING FOCUS ON BIOSPECIFC ANTIBODIES

6 CUSTOM ANTIBODY MARKET, BY SERVICE (Page No. - 52)
    6.1 INTRODUCTION
    6.2 ANTIBODY DEVELOPMENT
           6.2.1 ANTIBODY CHARACTERIZATION
                    6.2.1.1 Characterization eliminates antibodies with heterogeneities that may hamper research studies
           6.2.2 ANTIGEN PREPARATION
           6.2.3 IMMUNIZATION & HYBRIDOMA PRODUCTION
    6.3 ANTIBODY PRODUCTION & PURIFICATION
           6.3.1 RISING DEMAND FOR HIGH-QUALITY ANTIBODIES TO DRIVE MARKET GROWTH
    6.4 ANTIBODY FRAGMENTATION & LABELING
           6.4.1 INCREASED RESEARCH ACTIVITIES COUPLED WITH THE NEED FOR SPECIFIC ANTIBODY DETECTION TO DRIVE MARKET GROWTH

7 CUSTOM ANTIBODY MARKET, BY TYPE (Page No. - 60)
    7.1 INTRODUCTION
    7.2 MONOCLONAL ANTIBODIES
           7.2.1 MONOCLONAL ANTIBODIES SEGMENT TO DOMINATE THE MARKET DURING THE FORECAST PERIOD
    7.3 POLYCLONAL ANTIBODIES
           7.3.1 POLYCLONAL ANTIBODIES ARE PREFERRED IN PROTEOMICS RESEARCH FOR THE DETECTION OF DENATURED PROTEINS
    7.4 RECOMBINANT ANTIBODIES
           7.4.1 RESEARCH REPRODUCIBILITY OFFERED BY THESE ANTIBODIES IS DRIVING THEIR DEMAND
    7.5 OTHER CUSTOM ANTIBODIES

8 CUSTOM ANTIBODY MARKET, BY SOURCE (Page No. - 66)
    8.1 INTRODUCTION
    8.2 MICE
           8.2.1 MICE ARE THE MOST PREFERRED HOSTS FOR MONOCLONAL ANTIBODY PRODUCTION
    8.3 RABBITS
           8.3.1 ANTIBODIES DEVELOPED IN RABBITS ELIMINATE THE LIMITATION OF SELF-ANTIGEN RECOGNITION IN HUMANS
    8.4 OTHER SOURCES

9 CUSTOM ANTIBODY MARKET, BY RESEARCH AREA (Page No. - 70)
    9.1 INTRODUCTION
    9.2 ONCOLOGY
           9.2.1 USE OF ANTIBODIES HAS INCREASED CONSIDERABLY IN CANCER RESEARCH
    9.3 INFECTIOUS DISEASES
           9.3.1 ANTIBODIES ARE WIDELY USED IN R&D FOR THE DEVELOPMENT OF VACCINES & THERAPEUTICS AGAINST VARIOUS INFECTIOUS DISEASES
    9.4 IMMUNOLOGY
           9.4.1 ASSESSMENT OF CELL SURFACE ANTIGENS USING ANTIBODIES FORMS AN IMPORTANT FIELD OF RESEARCH IN IMMUNOLOGY
    9.5 NEUROBIOLOGY
           9.5.1 NEUROBIOLOGY IS ONE OF THE FASTEST-GROWING SEGMENTS IN TERMS OF RESEARCH BEING UNDERTAKEN UTILIZING ANTIBODIES
    9.6 STEM CELLS
           9.6.1 AVAILABILITY OF HIGH-QUALITY ANTIBODIES HAS BOOSTED STEM CELL RESEARCH
    9.7 CARDIOVASCULAR DISEASE
           9.7.1 IDENTIFICATION & CHARACTERIZATION OF CVD BIOMARKERS IS AN IMPORTANT RESEARCH AREA UTILIZING ANTIBODIES
    9.8 OTHER RESEARCH AREAS

10 CUSTOM ANTIBODY MARKET, BY END USER (Page No. - 78)
     10.1 INTRODUCTION
     10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
             10.2.1 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ARE THE LARGEST END USERS OF CUSTOM ANTIBODIES
     10.3 ACADEMIC & RESEARCH INSTITUTES
             10.3.1 INCREASE IN DNA SEQUENCING STUDIES AND PROTEOMIC RESEARCH TO DRIVE MARKET GROWTH
     10.4 CONTRACT RESEARCH ORGANIZATIONS
             10.4.1 CONTRACT RESEARCH ORGANIZATIONS PROVIDE AFFORDABLE OUTLETS FOR COMPANIES AND ACADEMIA TO PURSUE NEW MEDICINES

11 CUSTOM ANTIBODY MARKET, BY REGION (Page No. - 84)
     11.1 INTRODUCTION (Page No. - 85)
     11.2 NORTH AMERICA
             11.2.1 US
                        11.2.1.1 Growing research in the field of structure-based drug design and therapeutic mAbs to drive market growth
             11.2.2 CANADA
                        11.2.2.1 Increasing genomic research to drive the adoption of custom antibodies in the coming years
     11.3 EUROPE
             11.3.1 GERMANY
                        11.3.1.1 High investments for the development of ADCs support the growth of the custom antibody market in Germany
             11.3.2 UK
                        11.3.2.1 Growing research investments to drive growth in the life science research market
             11.3.3 FRANCE
                        11.3.3.1 Expanding pipeline of therapeutic mAbs along with increasing investments in research are supporting market growth
             11.3.4 ITALY
                        11.3.4.1 Growing proteomics and genomics research at the academic level to play a key role in market growth in Italy
             11.3.5 SPAIN
                        11.3.5.1 Increasing focus on the advancement of translational personalized medicine is expected to drive market growth
             11.3.6 REST OF EUROPE
     11.4 ASIA PACIFIC
             11.4.1 JAPAN
                        11.4.1.1 Large number of research initiatives toward the development of various ADCs are supporting market growth in Japan
             11.4.2 CHINA
                        11.4.2.1 China is one of the fastest-growing markets in the research sector and is expected to dominate the market in the coming years
             11.4.3 INDIA
                        11.4.3.1 Research for generic mAbs and fusion mAbs as therapeutics is expected to propel the custom antibody market in the country
             11.4.4 REST OF ASIA PACIFIC
     11.5 LATIN AMERICA
             11.5.1 INCREASING APPLICATIONS OF RESEARCH-SPECIFIC CUSTOM ANTIBODIES TO DRIVE MARKET GROWTH IN LATIN AMERICA
     11.6 MIDDLE EAST & AFRICA
             11.6.1 GROWING FOCUS OF PHARMACEUTICAL COMPANIES ON AFRICA TO DRIVE THE MARKET FOR CUSTOM ANTIBODIES IN THE REGION

12 COMPETITIVE LANDSCAPE (Page No. - 135)
     12.1 INTRODUCTION
     12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY MARKET PLAYERS
     12.3 MARKET SHARE ANALYSIS
     12.4 GROWTH STRATEGIES ADOPTED BY MAJOR AND EMERGING PLAYERS
             12.4.1 CUSTOM ANTIBODY MARKET: KEY DEALS (JANUARY 2018 TO APRIL 2021)
             12.4.2 CUSTOM ANTIBODY MARKET: KEY EXPANSIONS (JANUARY 2018 TO APRIL 2021)
     12.5 CUSTOM ANTIBODY MARKET: COMPANY EVALUATION MATRIX, 2020
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS

13 COMPANY PROFILES (Page No. - 141)
     13.1 KEY MARKET PLAYERS
             13.1.1 THERMO FISHER SCIENTIFIC, INC.
                        13.1.1.1 Business overview
                        13.1.1.2 Services offered
                        13.1.1.3 SWOT analysis
                        13.1.1.4 Recent developments
                        13.1.1.5 MnM view
             13.1.2 GENSCRIPT
                        13.1.2.1 Business overview
                        13.1.2.2 Services offered
                        13.1.2.3 SWOT analysis
                        13.1.2.4 Recent developments
                        13.1.2.5 MnM view
             13.1.3 ABCAM PLC
                        13.1.3.1 Business overview
                        13.1.3.2 Services offered
                        13.1.3.3 SWOT analysis
                        13.1.3.4 Recent developments
                        13.1.3.5 MnM view
             13.1.4 CELL SIGNALING TECHNOLOGY, INC.
                        13.1.4.1 Business overview
                        13.1.4.2 Services offered
                        13.1.4.3 Recent developments
             13.1.5 BIO-RAD LABORATORIES, INC.
                        13.1.5.1 Business overview
                        13.1.5.2 Services offered
                        13.1.5.3 SWOT analysis
             13.1.6 MERCK KGAA
                        13.1.6.1 Business overview
                        13.1.6.2 Services offered
                        13.1.6.3 SWOT analysis
                        13.1.6.4 Recent developments
             13.1.7 AGILENT TECHNOLOGIES, INC.
                        13.1.7.1 Business overview
                        13.1.7.2 Services offered
                        13.1.7.3 Recent developments
             13.1.8 BIOLEGEND, INC.
                        13.1.8.1 Business overview
                        13.1.8.2 Services offered
                        13.1.8.3 Recent developments
             13.1.9 ROCKLAND IMMUNOCHEMICALS, INC.
                        13.1.9.1 Business overview
                        13.1.9.2 Services offered
             13.1.10 PROMAB BIOTECHNOLOGIES, INC.
                        13.1.10.1 Business overview
                        13.1.10.2 Services offered
             13.1.11 INNOVAGEN AB
                        13.1.11.1 Business overview
                        13.1.11.2 Services offered
             13.1.12 PROTEOGENIX
                        13.1.12.1 Business overview
                        13.1.12.2 Services offered
             13.1.13 BIO-TECHNE
                        13.1.13.1 Business overview
                        13.1.13.2 Services offered
             13.1.14 CREATIVE DIAGNOSTICS
                        13.1.14.1 Business overview
                        13.1.14.2 Services offered
             13.1.15 SINO BIOLOGICAL, INC.
                        13.1.15.1 Business overview
                        13.1.15.2 Services offered
             13.1.16 RAYBIOTECH, INC.
                        13.1.16.1 Business overview
                        13.1.16.2 Services offered
             13.1.17 ABBIOTEC, INC.
                        13.1.17.1 Business overview
                        13.1.17.2 Services offered
             13.1.18 PROSCI
                        13.1.18.1 Business overview
                        13.1.18.2 Services offered
             13.1.19 BOSTER BIOLOGICAL TECHNOLOGY
                        13.1.19.1 Business overview
                        13.1.19.2 Services offered
             13.1.20 CAPRALOGICS, INC.
                        13.1.20.1 Business overview
                        13.1.20.2 Services offered

14 APPENDIX (Page No. - 181)
     14.1 DISCUSSION GUIDE
     14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     14.3 AVAILABLE CUSTOMIZATIONS
     14.4 RELATED REPORTS
     14.5 AUTHOR DETAILS


LIST OF TABLES (166 Tables)

TABLE 1 CUSTOM ANTIBODY MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 2 GLOBAL PHARMACEUTICAL R&D EXPENDITURE, 2010–2025 (USD BILLION)
TABLE 3 CUSTOM ANTIBODY MARKET: PORTER’S FIVE FORCES ANALYSIS
TABLE 4 CUSTOM ANTIBODY MARKET, BY SERVICE, 2019–2026 (USD MILLION)
TABLE 5 ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 6 ANTIBODY DEVELOPMENT MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 7 ANTIBODY CHARACTERIZATION MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 8 ANTIGEN PREPARATION MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 9 IMMUNIZATION & HYBRIDOMA PRODUCTION MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 10 ANTIBODY PRODUCTION & PURIFICATION MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 11 ANTIBODY FRAGMENTATION & LABELING MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 12 CUSTOM ANTIBODY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 13 CUSTOM MONOCLONAL ANTIBODIES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 14 CUSTOM POLYCLONAL ANTIBODIES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 15 CUSTOM RECOMBINANT ANTIBODIES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 16 OTHER CUSTOM ANTIBODIES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 17 CUSTOM ANTIBODY MARKET, BY SOURCE, 2019–2026 (USD MILLION)
TABLE 18 CUSTOM ANTIBODY MARKET FOR MICE, BY REGION, 2019–2026 (USD MILLION)
TABLE 19 CUSTOM ANTIBODY MARKET FOR RABBITS, BY REGION, 2019–2026 (USD MILLION)
TABLE 20 CUSTOM ANTIBODY MARKET FOR OTHER SOURCES, BY REGION, 2019–2026 (USD MILLION)
TABLE 21 CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019–2026 (USD MILLION)
TABLE 22 CUSTOM ANTIBODY MARKET FOR ONCOLOGY, BY REGION, 2019–2026 (USD MILLION)
TABLE 23 CUSTOM ANTIBODY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019–2026 (USD MILLION)
TABLE 24 CUSTOM ANTIBODY MARKET FOR IMMUNOLOGY, BY REGION, 2019–2026 (USD MILLION)
TABLE 25 CUSTOM ANTIBODY MARKET FOR NEUROBIOLOGY, BY REGION, 2019–2026 (USD MILLION)
TABLE 26 CUSTOM ANTIBODY MARKET FOR STEM CELLS, BY REGION, 2019–2026 (USD MILLION)
TABLE 27 CUSTOM ANTIBODY MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2019–2026 (USD MILLION)
TABLE 28 CUSTOM ANTIBODY MARKET FOR OTHER RESEARCH AREAS, BY REGION, 2019–2026 (USD MILLION)
TABLE 29 CUSTOM ANTIBODY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 30 CUSTOM ANTIBODY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 31 CUSTOM ANTIBODY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2019–2026 (USD MILLION)
TABLE 32 CUSTOM ANTIBODY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 33 CUSTOM ANTIBODY MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 34 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 35 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019–2026 (USD MILLION)
TABLE 36 NORTH AMERICA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 37 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 38 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019–2026 (USD MILLION)
TABLE 39 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019–2026 (USD MILLION)
TABLE 40 NORTH AMERICA: CUSTOM ANTIBODY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 41 US: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019–2026 (USD MILLION)
TABLE 42 US: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 43 US: CUSTOM ANTIBODY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 44 US: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019–2026 (USD MILLION)
TABLE 45 US: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019–2026 (USD MILLION)
TABLE 46 US: CUSTOM ANTIBODY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 47 CANADA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019–2026 (USD MILLION)
TABLE 48 CANADA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 49 CANADA: CUSTOM ANTIBODY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 50 CANADA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019–2026 (USD MILLION)
TABLE 51 CANADA: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019–2026 (USD MILLION)
TABLE 52 CANADA: CUSTOM ANTIBODY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 53 EUROPE: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 54 EUROPE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019–2026 (USD MILLION)
TABLE 55 EUROPE: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 56 EUROPE: CUSTOM ANTIBODY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 57 EUROPE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019–2026 (USD MILLION)
TABLE 58 EUROPE: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019–2026 (USD MILLION)
TABLE 59 EUROPE: CUSTOM ANTIBODY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 60 GERMANY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019–2026 (USD MILLION)
TABLE 61 GERMANY: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 62 GERMANY: CUSTOM ANTIBODY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 63 GERMANY: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019–2026 (USD MILLION)
TABLE 64 GERMANY: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019–2026 (USD MILLION)
TABLE 65 GERMANY: CUSTOM ANTIBODY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 66 UK: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019–2026 (USD MILLION)
TABLE 67 UK: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 68 UK: CUSTOM ANTIBODY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 69 UK: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019–2026 (USD MILLION)
TABLE 70 UK: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019–2026 (USD MILLION)
TABLE 71 UK: CUSTOM ANTIBODY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 72 FRANCE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019–2026 (USD MILLION)
TABLE 73 FRANCE: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 74 FRANCE: CUSTOM ANTIBODY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 75 FRANCE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019–2026 (USD MILLION)
TABLE 76 FRANCE: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019–2026 (USD MILLION)
TABLE 77 FRANCE: CUSTOM ANTIBODY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 78 ITALY: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019–2026 (USD MILLION)
TABLE 79 ITALY: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 80 ITALY: CUSTOM ANTIBODY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 81 ITALY: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019–2026 (USD MILLION)
TABLE 82 ITALY: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019–2026 (USD MILLION)
TABLE 83 ITALY: CUSTOM ANTIBODY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 84 SPAIN: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019–2026 (USD MILLION)
TABLE 85 SPAIN: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 86 SPAIN: CUSTOM ANTIBODY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 87 SPAIN: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019–2026 (USD MILLION)
TABLE 88 SPAIN: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019–2026 (USD MILLION)
TABLE 89 SPAIN: CUSTOM ANTIBODY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 90 ROE: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019–2026 (USD MILLION)
TABLE 91 ROE: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 92 ROE: CUSTOM ANTIBODY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 93 ROE: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019–2026 (USD MILLION)
TABLE 94 ROE: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019–2026 (USD MILLION)
TABLE 95 ROE: CUSTOM ANTIBODY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 96 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 97 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019–2026 (USD MILLION)
TABLE 98 ASIA PACIFIC: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 99 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 100 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019–2026 (USD MILLION)
TABLE 101 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019–2026 (USD MILLION)
TABLE 102 ASIA PACIFIC: CUSTOM ANTIBODY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 103 JAPAN: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019–2026 (USD MILLION)
TABLE 104 JAPAN: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 105 JAPAN: CUSTOM ANTIBODY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 106 JAPAN: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019–2026 (USD MILLION)
TABLE 107 JAPAN: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019–2026 (USD MILLION)
TABLE 108 JAPAN: CUSTOM ANTIBODY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 109 CHINA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019–2026 (USD MILLION)
TABLE 110 CHINA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 111 CHINA: CUSTOM ANTIBODY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 112 CHINA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019–2026 (USD MILLION)
TABLE 113 CHINA: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019–2026 (USD MILLION)
TABLE 114 CHINA: CUSTOM ANTIBODY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 115 INDIA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019–2026 (USD MILLION)
TABLE 116 INDIA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 117 INDIA: CUSTOM ANTIBODY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 118 INDIA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019–2026 (USD MILLION)
TABLE 119 INDIA: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019–2026 (USD MILLION)
TABLE 120 INDIA: CUSTOM ANTIBODY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 121 ROAPAC: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019–2026 (USD MILLION)
TABLE 122 ROAPAC: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 123 ROAPAC: CUSTOM ANTIBODY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 124 ROAPAC: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019–2026 (USD MILLION)
TABLE 125 ROAPAC: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019–2026 (USD MILLION)
TABLE 126 ROAPAC: CUSTOM ANTIBODY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 127 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019–2026 (USD MILLION)
TABLE 128 LATIN AMERICA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 129 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 130 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019–2026 (USD MILLION)
TABLE 131 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019–2026 (USD MILLION)
TABLE 132 LATIN AMERICA: CUSTOM ANTIBODY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 133 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY SERVICE, 2019–2026 (USD MILLION)
TABLE 134 MIDDLE EAST & AFRICA: ANTIBODY DEVELOPMENT MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 135 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 136 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY SOURCE, 2019–2026 (USD MILLION)
TABLE 137 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY RESEARCH AREA, 2019–2026 (USD MILLION)
TABLE 138 MIDDLE EAST & AFRICA: CUSTOM ANTIBODY MARKET, BY END USER, 2019–2026 (USD MILLION)
TABLE 139 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
TABLE 140 DEALS, JANUARY 2018–MARCH 2021
TABLE 141 GENSCRIPT: BUSINESS OVERVIEW
TABLE 142 DEALS, JANUARY 2018–MARCH 2021
TABLE 143 ABCAM PLC: BUSINESS OVERVIEW
TABLE 144 DEALS, JANUARY 2018–MARCH 2021
TABLE 145 CELL SIGNALING TECHNOLOGY, INC.: BUSINESS OVERVIEW
TABLE 146 EXPANSIONS, JANUARY 2018–MARCH 2021
TABLE 147 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
TABLE 148 MERCK KGAA.: BUSINESS OVERVIEW
TABLE 149 DEALS, JANUARY 2018–MARCH 2021
TABLE 150 EXPANSIONS, JANUARY 2018–MARCH 2021
TABLE 151 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
TABLE 152 EXPANSIONS, JANUARY 2018–MARCH 2021
TABLE 153 BIOLEGEND, INC.: BUSINESS OVERVIEW
TABLE 154 DEALS, JANUARY 2018–MARCH 2021
TABLE 155 ROCKLAND IMMUNOCHEMICALS, INC.: BUSINESS OVERVIEW
TABLE 156 PROMAB BIOTECHNOLOGIES, INC: BUSINESS OVERVIEW
TABLE 157 INNOVAGEN AB: BUSINESS OVERVIEW
TABLE 158 PROTEOGENIX: BUSINESS OVERVIEW
TABLE 159 BIO-TECHNE: BUSINESS OVERVIEW
TABLE 160 CREATIVE DIAGNOSTICS: BUSINESS OVERVIEW
TABLE 161 SINO BIOLOGICAL, INC.: BUSINESS OVERVIEW
TABLE 162 RAYBIOTECH, INC.: BUSINESS OVERVIEW
TABLE 163 ABBIOTEC, INC.: BUSINESS OVERVIEW
TABLE 164 PROSCI: BUSINESS OVERVIEW
TABLE 165 BOSTER BIOLOGICAL TECHNOLOGY: BUSINESS OVERVIEW
TABLE 166 CAPRALOGICS, INC.: BUSINESS OVERVIEW


LIST OF FIGURES (29 Figures)

FIGURE 1 BREAKDOWN OF PRIMARIES: CUSTOM ANTIBODY MARKET
FIGURE 2 DATA TRIANGULATION METHODOLOGY
FIGURE 3 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE-BASED ESTIMATION)
FIGURE 4 CUSTOM ANTIBODY MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2020
FIGURE 5 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
FIGURE 6 CUSTOM ANTIBODY MARKET (SUPPLY SIDE): CAGR PROJECTIONS
FIGURE 7 CUSTOM ANTIBODY MARKET SHARE, BY SERVICE, 2020 VS. 2026
FIGURE 8 CUSTOM ANTIBODY MARKET SHARE, BY TYPE, 2020
FIGURE 9 CUSTOM ANTIBODY MARKET SHARE, BY SOURCE, 2021 VS. 2026
FIGURE 10 CUSTOM ANTIBODY MARKET SHARE, BY RESEARCH AREA, 2020
FIGURE 11 CUSTOM ANTIBODY MARKET SHARE, BY END USER, 2020
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE CUSTOM ANTIBODY MARKET
FIGURE 13 QUALITY CONCERNS OVER CATALOG ANTIBODIES TO DRIVE MARKET GROWTH
FIGURE 14 MONOCLONAL ANTIBODIES ACCOUNTED FOR THE LARGEST SHARE OF THE NORTH AMERICAN CUSTOM ANTIBODY MARKET IN 2020
FIGURE 15 MICE ARE THE LARGEST SOURCE OF CUSTOM ANTIBODIES
FIGURE 16 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH IN THE CUSTOM ANTIBODY MARKET FROM 2021 TO 2026
FIGURE 17 NUMBER OF PATENTS GRANTED FOR CUSTOM ANTIBODIES, JANUARY 2010–DECEMBER 2020
FIGURE 18 CUSTOM ANTIBODY MARKET: GEOGRAPHIC SNAPSHOT (2021)
FIGURE 19 NORTH AMERICA: CUSTOM ANTIBODY MARKET SNAPSHOT
FIGURE 20 ASIA PACIFIC: CUSTOM ANTIBODY MARKET SNAPSHOT
FIGURE 21 CUSTOM ANTIBODY MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2020)
FIGURE 22 CUSTOM ANTIBODY MARKET: COMPANY EVALUATION MATRIX, 2020
FIGURE 23 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2019)
FIGURE 24 GENSCRIPT: COMPANY SNAPSHOT (2019)
FIGURE 25 ABCAM PLC: COMPANY SNAPSHOT (2020)
FIGURE 26 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2020)
FIGURE 27 MERCK KGAA.: COMPANY SNAPSHOT (2020)
FIGURE 28 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020)
FIGURE 29 BIO-TECHNE: COMPANY SNAPSHOT (2020)

This market research study involved the extensive use of secondary sources, directories, and databases to identify and collect relevant information on the global custom antibody market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, scientists & research scholars, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information and to assess market growth prospects. The global size of the custom antibody market (estimated through various secondary research approaches) was then triangulated with inputs from primary respondents to arrive at the final market size.

Secondary Research

The secondary sources referred to for this research study include publications from government sources, such as the Antibody Society, Pharmaceutical Research and Manufacturers of America (PhRMA), National Institutes of Health (NIH), American Medical Association (AMA), Association of Medical Laboratory Immunologists (AMLI), National Cancer Institute (NCI), American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), European Medicines Agency (EMA), British Society for Immunology (BSI), World Health Organization (WHO), Company Websites, Annual Reports, SEC Filings, Press Releases, Investor Presentations, EvaluatePharma, ScienceDirect, News Articles, Journals, and Paid Databases. Secondary data was collected and analyzed to arrive at the overall size of the global custom antibody market, which was validated through primary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global custom antibody market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (such as personnel from pharmaceutical & biotechnology companies and academic & research institutes as well as purchase managers in healthcare provider organizations) and the supply side (such as C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, service providers, and channel partners, among others) across five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Approximately 50% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

Custom Antibody Market  Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Data Triangulation

After arriving at the overall market size, from the market size estimation process explained above, the custom antibody market was split into segments and subsegments. to complete the overall market engineering process and to arrive at the exact statistics for all segments and subsegments, the data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the  custom antibody market

Report Objectives

  • To define, describe, segment, and forecast the custom antibody market on the basis of services, type, research area, source, and end user.
  • To provide detailed information about the factors influencing market growth, such as drivers, restraints, opportunities, and challenges
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall custom antibody market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments concerning five main regions, namely, North America, Europe, the Asia Pacific (APAC), Latin America (LATAM), and the Middle East & Africa (MEA)
  • To strategically profile the key players in the global custom antibody market and comprehensively analyze their core competencies2 and market rankings
  • To track and analyze competitive developments, such as product launches, acquisitions, collaborations, expansions, and partnerships in the custom antibody market

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographical Analysis

  • Further breakdown of the European custom antibody market into countries from the Rest of Europe segment.
  • Further breakdown of the Asia Pacific custom antibody market into countries from the Rest of the APAC segment.
  • Further breakdown of Latin America and the Middle East & Africa custom antibody market into countries.

Company Information

Detailed analysis and profiling of additional market players (up to 5) inclusive of:

  • Business Overview
  • Financial Information
  • Product Offered
  • Developments (Last three years)
COVID-19

Get in-depth analysis of the COVID-19 impact on the Custom Antibody Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Custom Antibody Market

Request For Special Pricing
Report Code
BT 6817
Published ON
May, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Custom Antibody Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home